3 assets in Lipid-Cell Variant Infiltrating Bladder Urothelial Carcinoma

Therapeutic assets addressing Lipid-Cell Variant Infiltrating Bladder Urothelial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Lipid-Cell Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Lipid-Cell Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Lipid-Cell Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)